unreviewed

UGT1A1

0 reactions · 0 pathways

What it does, reaction by reaction

0 reactions

This enzyme appears only in the regulation table, with no catalysed step recorded.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Heme Degradation (Bilirubin Pathway)

Accelerated by

Bilirubin availability; maturation/induction of hepatic expression

Inhibited by

UGT1A1 variants; some drugs that inhibit or compete for glucuronidation

Hormonal control

Developmental regulation is major; neonatal activity is low. Hormonal effects are indirect through hepatic maturation and cholestatic states

Disorders

Crigler-Najjar syndrome type I
UGT1A1 AR

Severe neonatal jaundice, kernicterus, death without transplant
Gilbert syndrome
UGT1A1 AR / polymorphism

Mild intermittent jaundice with fasting, illness or stress; otherwise benign

Provenance. Source: Regulation table only. EC numbers, gene symbols and disease links were written from standard biochemistry rather than the uploaded documents, and stay unreviewed until checked against Expasy ENZYME, BRENDA or OMIM.

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

1
Low-dose l-carnitine supplementation attenuates hepatic lipid accumulation in chow-fed mice: Insights from integrated multi-omics analysis.
Zhang Z, Ding B, Zhang L, Zhang L, Huang Y. · 2026-09-10

open access unreviewed
2
Spatiotemporal synergistic drug co-delivery via a dual-crosslinked liposomal platform for potent NETs blockade in rheumatoid arthritis.
Wang Q, Ren J, Wen X, Hua Y, Liao Z, Weng Y, Cai F, Qin X, Zeng Y. · 2026-08-24

unreviewed
3
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
Akhtar N, Barnes J, Gardiner P, Gurley BJ, Ko R, Koturbash I, Patel D, van Breemen RB, Roe AL. · 2026-06-27

cited 1× open access unreviewed
4
Digeda-8 formula attenuates cholestatic liver injury in rats by restoring bile acid transport and suppressing inflammation: An integrated metabolomics and proteomics approach.
Bayoude A, Yi R, Zhao Y, Runa A, Ming M, Hu S, Jirimu B. · 2026-06-24

unreviewed
5
Gut bacterial O-demethylation modulates systemic exposure to oral etoposide.
Tripathi A, Kyawt TE, Shin J, Won KJ, Armstrong AT, Ilktach G, Sullivan P, Weilbaker HA, Ko Y, Lee S, Lee W, … · 2026-02-13

cited 3× open access unreviewed
6
Assessment of reproductive risks of bisphenol S in male BALB/c mice through functional histological and multi-omics investigations.
Lin X, Liu H, Ma W, Lu S, Li B, Zhang W, Li N, Chen T. · 2026-08-18

unreviewed
7
Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicity.
Moy AT, D'Angelo LE, Hertz DL. · 2026-07-28

unreviewed
8
DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.
Gambron M, Peruzzi E, Perfler S, Montico M, Cecchin R, De Mattia E, Spina M, Lisanti C, Corsetti S, Foltran L… · 2026-06-09

open access unreviewed
9
Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center
Moorthy G, Sereika A, Kaul K, Parilla M, Alikhan M, Bouma M, Wake D, Hulick P, Dunnenberger H, Sabatini L, Ya… · 2026-10-01

open access unreviewed
10
Low Phospholipid-Associated Cholelithiasis in a Mother-Son Pair Associated With a Novel ABCB4 Frameshift Variant.
Yang HM, Liu J, Zhang Z. · 2026-10-02

open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.